Cannabis use Psychotic illness
Conditions
Interventions
PET and [18F]MK9470, a CB1 receptor ligand as a measure of CB1 receptor availability in vivo.
Sponsors
Universiteit Maastricht, The Netherlands
UZ Gasthuisberg en Katholieke Universiteit Leuven, Belgium
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age 18-50 years 2. Life-time use of cannabis without having experienced negative effects 3. Being capable to consent and having signed informed consent 4. BMI between 18.5 and 27 5. Clinical diagnosis of non-affective psychosis according to DSM-IV (applies only to patients)
Exclusion criteria
Exclusion criteria: 1. Head trauma with loss of consciousness of more than 1 hour 2. Respiratory, cardiovasculatory, neurological disease, severe renal or liver dysfunction 3. Alcohol use in excess of 5 units per day 4. Weekly use of illicit drugs other than cannabis 5. Current use of antipsychotic medication or medication known to interfere with the CB1 receptor 6. Pregnancy and breast-feeding 7. Personal or family history of psychosis (applies only to controls)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Striatal and extrastriatal [18F]MK9470 binding. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Differences in striatal and extrastriatal [18F]MK9470 binding as a function of genotypic variation of functional polymorphisms like the COMT Val158Met polymorphism | — |
Contacts
Public ContactCecile Henquet
Maastricht University Department of Psychiatry and Neuropsychology PO Box 616 (loc. Vijverdal.)
Outcome results
None listed